Premium
Promotion of PDT Efficacy by a Bcl‐2 Antagonist
Author(s) -
Kessel David
Publication year - 2007
Publication title -
photochemistry and photobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.818
H-Index - 131
eISSN - 1751-1097
pISSN - 0031-8655
DOI - 10.1111/j.1751-1097.2007.00267.x
Subject(s) - endoplasmic reticulum , autophagy , photodynamic therapy , organelle , apoptosis , programmed cell death , antagonist , microbiology and biotechnology , viability assay , cancer research , function (biology) , chemistry , phototoxicity , biology , receptor , biochemistry , in vitro , organic chemistry
Photodynamic therapy (PDT) directed against the endoplasmic reticulum (ER) is also known to target antiapoptotic Bcl‐2 family proteins. This effect is associated with the initiation of both apoptosis, a cell death pathway, and autophagy, an organelle recycling system that can lead to survival or cell death. In this study, we examined the ability of the Bcl‐2 antagonist HA14‐1 to promote the photodynamic efficacy of PDT directed at the ER. At concentrations that independently caused only a small loss of viability, HA14‐1 markedly enhanced the proapoptotic and phototoxic effects of ER photodamage. These results provide additional evidence that the antiapoptotic properties of Bcl‐2 constitute an important determinant of photokilling, and demonstrate that synergistic effects can result when PDT is coupled with pharmacologic suppression of Bcl‐2 function.